U.S. Nuclear Medicine Market (2024 - 2030) Size, Share & Trends Analysis Report By Product (Diagnostic (SPECT, PET), Therapeutic (Alpha, Beta Emitters, Brachytherapy)), By Application, By End-use, By Country, And Segment Forecasts

Market Segmentation

U.S. Nuclear Medicine Product Outlook (Revenue, USD Million, 2018 - 2030)
- Diagnostic Products
  - SPECT
    - TC-99m
    - TL-201
    - GA-67
    - I-123
    - Other SPECT Products
  - PET
    - F-18
    - SR-82/RB-82
    - Other PET products
- Therapeutic Products
  - Alpha Emitters
    - RA-223
    - Others
  - Beta Emitters
    - I-131
    - Y-90
    - SM-153
    - Re-186
    - Lu-117
    - Other Beta Emitters
  - Brachytherapy
    - Cesium-131
    - Iodine-125
    - Palladium-103
    - Iridium-192
    - Other Brachytherapy Products
U.S. Nuclear Medicine Application Outlook (Revenue, USD Million, 2018 - 2030)
- Cardiology
  - SPECT
  - PET
  - Therapeutic Applications
- Neurology
- Oncology
- Thyroid
  - SPECT
  - Therapeutic Applications
- Lymphoma
- Bone Metastasis
  - SPECT
- Therapeutic Applications
- Endocrine Tumor
- Pulmonary Scans
- Others
U.S. Nuclear Medicine End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals & Clinics
- Diagnostic Centers
- Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments